期刊文献+

羟基喜树碱、四氢叶酸钙、5-Fu方案治疗胃癌的临床观察

Clinical Observation on HCF Regimen in Treating Stomach Neoplasm
下载PDF
导出
摘要 目的 探讨羟基喜树碱、四氢叶酸钙、5 Fu方案治疗胃癌的临床疗效及价值。方法 用HCPT +CF +5 FU方案对 5 8例 ,晚期胃癌患者进行临床治疗观察。结果 全组患者近期有效率 5 6 .9% ,其中CR 13.8% ,PR 4 3.1%。结论 本方案对晚期胃癌疗效肯定 ,毒副反应小 。 Objective To discuss the clinical effect of the combined regimen of HCPT,CF and 5 FU in treating stomach neoplasm. Methods The combined regimen of HCPT 10mg,VD,D1 5,CF 200mg,VD,D1 5,5 FU,0.75g,VD,D1 5 was given to 58 cases of advanced stomach neoplasm. Results The total effective rate of all the 58 patients reached 56.9%,in which CR was 13.8% and PR was 43.1%. Conclusions This combined regimen is of approved effect in treating advanced stomach neoplasm with little side effect;it is worth being further studied in clinical chemotherapy for stomach neoplasm.
出处 《西南军医》 2004年第3期11-11,14,共2页 Journal of Military Surgeon in Southwest China
关键词 胃癌 羟基喜树碱 四氢叶酸钙 5-氟尿嘧啶 化疗 stomach neoplasm HCPT CF 5-FU chemotherapy
  • 相关文献

参考文献2

二级参考文献29

  • 1[1]Rothenberg ML.Efficacy and toxicity of irinotecan in patients with colorectal cancer[J].Semin Oncol,1998,25(5 suppl 11):39.
  • 2[2]Miya T, Fujikawa R, Fukushima J,et al.Bradycardia induced by irinotecan:a case report[J].Jpn J Clin Oncol,1998,28(11):709.
  • 3[3]Rivory LP,Chatelut E,Canal P,et al. Kinetics of the in vivo interconversion of the carboxylate and lactone for-ms of irinotecan(CPT-11)and of its metabolite SN-38 in patients[J].Cancer Res,1994,54(24):6 330.
  • 4[4]Cunningham D,Pyrhonen S,James RD,et al.Random-ised trial of irinotecan plus supportive care versus sup-portive care alone after fluorouracil failure for patients with metastatic colorectal cancer[J].Lancet,1998,352(9138):1 413.
  • 5[5]Rougier P,Van Cutsem E,Bajetta E,et al.Randomised trial of irinotecan versus fluorouracil by continuous in-fusion after fluorouracil failure in patients with metas-tatic colorectal cancer[J].Lancet,1998,352(9138):1 407.
  • 6[6]Rowinsky EK,Baker SD,Burks K,et al.High-dose to-potecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer:a phaseⅡ and pharmacodynamic study[J].Ann Oncol,1998,9(2):173.
  • 7[7]Perez Soler R,Fossella FV,Glisson BS,et al.PhaseⅡstudy of topotecan in patients with advanced non-sm-all-cell lung cancer previously untreated with chemo-therapy[J].J Clin Oncol,1996,14(2):503.
  • 8[8]Gerrits CJ,Burris H,Schellens JH,et al.Oral topotecan given once or twice daily for ten days:a phase I pharmacology study in adult patients with solid tumors[J].Clin Cancer Res,1998,4(5):1 153.
  • 9[9]Perez Soler R,Glisson BS,Lee JS,et al.Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan[J].J Clin Oncol,1996,14(10):2 785.
  • 10[10]Langevin AM,Casto DT,Thomas PJ,et al.Phase I trial of 9-aminocamptothecin in children with refractory solid tumors:a pediatric oncology group study[J].J Clin Oncol,1998,16(7):2 494.

共引文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部